Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

4528 - Systemic Therapy in 2nd-Line Metastatic Triple Negative Breast Cancer (mTNBC): A Systematic Literature Review (SLR) and Meta-Analysis (MA) of Efficacy

Date

29 Sep 2019

Session

Poster Display session 2

Topics

Tumour Site

Breast Cancer

Presenters

Peter Kaufman

Citation

Annals of Oncology (2019) 30 (suppl_5): v104-v142. 10.1093/annonc/mdz242

Authors

P.A. Kaufman1, C.S. Kwon2, J. Feliciano3, T. Westley2, A. Forsythe2, P. Garfin3, L. Brown3

Author affiliations

  • 1 Breast Oncology, Division Of Hematology/oncology, University of Vermont Cancer Center, 05401 - Burlington/US
  • 2 Health Technology Assessment, Purple Squirrel Economics, 10010 - New York/US
  • 3 Global Health Economics & Outcomes Research, Seattle Genetics, Inc., Bothell/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4528

Background

Triple negative breast cancer carries a poor prognosis. Cytotoxic chemotherapy (chemo) is the standard of care. Recent data demonstrate that immunotherapy and anti-body drug conjugate based therapy can improve outcomes. Nevertheless survival remains poor. This SLR and MA was performed to assess the efficacy of current treatments for 2 nd line (2L) mTNBC.

Methods

EMBASE, MEDLINE, Cochrane databases were systematically searched from database inception to December 2018 for relevant studies of mTNBC with any systemic therapies in metastatic disease. Relevant congresses proceedings since 2016 and ClinicalTrials.gov were also searched. This SLR followed PRISMA guidelines with scope defined in terms of PICOS criteria (Population, Intervention, Comparators, Outcomes and Study design). Weighted averages (WA) for outcomes by treatment arm and line of therapy (LOT) were calculated. In addition, MA of overall response rate (ORR) among patients receiving single agent chemo (single chemo) as 2L and first line or later (1L+) was carried out using random-effects modeling for ORR.

Results

44 original studies were selected: 22 with 1L+, 7 with 2L, 15 with 2L or later (2L+). WAs of outcomes are presented in the Table. WAs of ORR for single chemo were less than ORR for combination chemo or chemo & biologics. No treatment showed consistently better survival over other treatments across all 3 groupings. MA of ORR in patients receiving single chemo as 2L and 1L+ were 11.9% (95% CI: 4.6, 20.8) and 15.6% (95% CI: 8.8-32.9), respectively. Table. Weighted Averages of Clinical Outcomes by Treatment and Line of Therapy.Table:

360P

TreatmentLine of TherapyOverall Response Rate (%)Progression Free Survival (median months)Overall Survival (median months)

Single agent

chemotherapy

1L+14.62.310.8
2L14.32.412.6
2L+-3.112.3

Combination

chemotherapy

1L+29.74.410.5
2L31.04.110.0
2L+-2.98.1

Chemotherapy &

Biologics

1L+22.62.910.6
2L35.85.617.9
2L+21.23.510.7

Conclusions

There is no clear standard of care in 2L TNBC. Response rates are low for single chemo and although response rates improve with combination therapies, no treatment regimen has demonstrated definitive improvement in outcomes. These results reinforce the need for new treatment strategies for mTNBC after 1L.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Purple Squirrel Economics.

Funding

Seattle Genetics, Inc.

Disclosure

P.A. Kaufman: Full / Part-time employment: Seattle Genetics, Inc. J. Feliciano: Full / Part-time employment: Seattle Genetics, Inc. P. Garfin: Full / Part-time employment: Seattle Genetics, Inc. L. Brown: Full / Part-time employment: Seattle Genetics, Inc. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.